Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
This is a single site, parallel randomized, double blinded comparison of the safety, pharmacokinetics, and immunogenicity of a single 0.57 mg/kg dose of SYN060 to a single 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American and European sources. The study is open to healthy individuals on no medications that might confound the results of this safety study.
Epistemonikos ID: 962fe891d613612c78487d8df80803aafd24d567
First added on: Mar 23, 2022